Navigation Links
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
Date:6/3/2008

>

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. XIAFLEX(TM) (clostridial collagenase for injection) is in phase III of development for the treatment of Dupuytren's contracture and is in phase II of development for the treatment of Peyronie's disease and Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium also has options to all indications using XIAFLEX for non-topical formulations. Auxilium's transmucosal film product candidate for the treatment of overactive bladder is in phase I of development. Auxilium has one pain product using its transmucosal film delivery system in pre-clinical development and has rights to seven additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the interpretation of clinical data; the significance of clinical data to Auxilium, the patients suffering from Dupuytren's contracture and the physicians who treat these patients and the degree to which these individuals find the clinical data reported by Auxilium to be compelling; the contribution of the results of CORD I and CORD II, together with all the previous clinical and pre-clinical data, to the Biologics License Application for XIAFLEX for the treatment of Dupuytren's contracture (the "BLA"); the ti
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
5. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
6. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
7. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
8. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Fla. , July 22, 2014  Neurotrope Bioscience, ... signed a world-wide, exclusive license agreement with the Icahn ... ( Mount Sinai ) to utilize ... of Bryostatin-1 in the treatment of Niemann-Pick Type C ... are afflicted with Alzheimer-like symptoms. The license also covers ...
(Date:7/22/2014)... , July 22, 2014  ConvaTec, a privately-held ... Nigel Clerkin has been appointed chief financial officer ... Mr. Clerkin was previously executive vice president and chief ... -based biotechnology company.  Mr. Clerkin was part of ... at Elan, culminating in its sale to Perrigo, a ...
(Date:7/22/2014)... The steady decline of pharmaceutical sales ... rep-friendly specialties, according to the spring 2014 AccessMonitor™ ... ZS Associates.      AccessMonitor™ aggregates sales-call ... teams. The report examines how often approximately 325,000 ... sales reps who visit their offices. ...
Breaking Medicine Technology:Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5ConvaTec Names Nigel Clerkin Chief Financial Officer 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 2Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 3Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 4Even traditionally rep-friendly specialists will see fewer pharmaceutical sales reps this year, according to ZS Associates 5
(Date:7/22/2014)... 22, 2014 SkillSurvey Inc., the ... help employers make better hiring decisions, will be ... improve the engagement and retention of contingent workers ... IMAGE 2014 Conference being held in Orlando, Florida ... a case study featuring Metro Health, a hospital ...
(Date:7/22/2014)... The “Human Insulin Market by Product Type ... Human Insulin (Rapid Acting, Long Acting, Premixed)], by ... - Forecast to 2019” provides a detailed overview ... market trends, and strategies impacting the global human ... of the revenue and share analysis. , Browse ...
(Date:7/22/2014)... Dr. Larry Kaplan and concerned leading dentists ... Experts Benefit Dinner May 30, in St. Petersburg, FL. ... funds for the Improving Youth Literacy Campaign, in support ... The funds raised are providing hundreds of thousands of ... break the cycle of poverty. , Notables who ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 The ... insight into the specific market segment called disposable ... segment within the global healthcare equipment and supplies ... with needles, prefilled syringes, disposable medical catheters, wound ... gloves, adult incontinence products, blood glucose test strips, ...
(Date:7/22/2014)... Cloud+MD Office 2.0 is ... of medical software and services, designed by experienced ... produces “Actionable Information” to help Independent Physician Practices, ... Billing Services optimize a wide range of business ... Efficiency, Noticeable Cost Reductions and Better Patient Care. ...
Breaking Medicine News(10 mins):Health News:SkillSurvey to Present Research on Contingent Workers at National Association for Health Care Recruitment IMAGE 2014 Conference 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 5Health News:Dr. Larry Kaplan Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Dr. Larry Kaplan Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3Health News:Growth of Disposable Medical Supplies Market to 2019 Report Available at RnRMarketResearch.com 2Health News:Growth of Disposable Medical Supplies Market to 2019 Report Available at RnRMarketResearch.com 3Health News:Growth of Disposable Medical Supplies Market to 2019 Report Available at RnRMarketResearch.com 4Health News:Growth of Disposable Medical Supplies Market to 2019 Report Available at RnRMarketResearch.com 5Health News:Cloud-MD Software will soon Receive MU2 Certification 2
... joint becomes inflamed. Treatment is often difficult and recovery ... the pain of this common condition. ,Now, an ... with extracorporeal shock wave therapy. During the therapy, ultrasound ... takes two to three 20-minute shock wave treatments to ...
... located at the base of the hair follicle. Hair ... In many people with hair loss, however, // the ... of abnormal follicles entering longer resting phases and producing ... University of Pennsylvania School of Medicine have isolated stem ...
... say there could be a new way to help prevent ... // increase high-density lipoprotein levels, also known as good cholesterol. ... for heart disease. They are commonly used to lower low-density ... target is a low level of good cholesterol. In fact, ...
... Toronto conducted a study to examine whether current procedures ... antibiotics // unnecessarily. Out of an estimated 6.7 million ... Doctors also researched the use of throat cultures and ... who were prompted to seek medical help for their ...
... attention deficit/hyperactivity disorder (ADHD) affects up to 12 percent of ... increased attention problems at age 7 among kids was seen ... toddlers.The study tracked the number of hours kids watched television ... two hours of television a day. Three-year-olds watched about three ...
... warnings from the Food and Drug Administration may leave ... what they claim.// ,Some of the products ... Blocker, and Zone Fat Blocker.Many of these supplements claim ... consumers to lose weight without making any lifestyle changes. ...
Cached Medicine News:
... ALIF Allograft is processed from 100% cortical ... support. The graft is machined with a ... to graft migration. The intermedulary canal accommodates ... ALIF Allografts contain a relief orientation in ...
Lumbar Allograft with Osteoactive advantage. Promotes bone formation and faster incorporation. Derived from the proven technology behind Grafton DBM. Maintains structural integrity and strength....
Williams Micro Discectomy Instruments are designed to be used in the microsurgical treatment of herniated disks....
... Anteater Titanium Microdiscectomy System offers strength ... surgery. The boss anteater titanium microdiscectomy ... intervertebral discs provides for less invasive ... retractor is designed to provide low ...
Medicine Products: